Agios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma
SAGA Metals Announces Closing of Fully Subscribed Non-Brokered Private Placement and Provides Corporate Update